Summary

The sodium glucose cotransporter-2 inhibitor canagliflozin reduces HbA1C level in patients with type 2 diabetes mellitus (T2DM) and stage 3 chronic kidney disease (CKD), an effect that is more pronounced with higher levels of estimated glomerular filtration rate (eGFR), according to the results of a pooled analysis. This article presents the results of this pooled analysis of four randomized, double-blind, placebo-controlled Phase 3 trials that compared canagliflozin with placebo in patients with inadequately controlled T2DM and stage 3 CKD.